MRK Maintained by Argus Research -- Price Target Raised to $170
MRK Maintained by Argus Research -- Price Target Raised to $170 GuruFocus
Covered in this story
What has happened since
- Merck & Co. is down 5.2% since this was published, 56 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
Argus Research’s $170 target on $MRK is on the record and being tracked to Aug 2027 (12-month default), scored on the close that day.
Argus Research’s track record →Analyst targets on Merck & Co.
- RBC Capital Markets: $145 → $145 by Oct 2027 · Sector Perform via MarketBeat
- Cantor Fitzgerald: $142 → $145 by Oct 2027 · Neutral via MarketBeat
- Morgan Stanley: $143 → $177 by Oct 2027 · Overweight via MarketBeat
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MRK yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Merck & Co. →Dalsna Finance is currently tracking 35 stories mentioning Merck & Co., the earliest published 26 Jun 2026.
Summary aggregated from GuruFocus's public RSS feed. The full reporting belongs to GuruFocus — please read it on their site.